Medtech VC Fell 17.1% in Q1 2026 — But the Money Got Pickier, Not Scarcer

Medtech VC deal value fell 17.1% year over year in Q1 2026 — but the decline came off a record $16.1B in 2025, according to PitchBook data cited by Jordan Lisnow, COO and co-founder of CuffWay, in an analysis published on MedCity News. The headline number, Lisnow argues, misses what is actually happening in the sector.

Deal count fell only 3.7% YoY, while the median deal size climbed to $11.8M from 2025's already-record $10M. The money is not leaving medtech; it is concentrating into fewer, larger checks. On the private equity side, medtech PE deal count dropped roughly 41% YoY to 26 deals in Q1.

Is the 'medtech VC decline' thesis actually true?

Only partially. Lisnow, a former VC at Traverse Ventures, set out to test the widespread claim that "medtech VC is in decline" and expected shrinking investor interest, inflated valuations and a weak exit environment. The data contradicted two of his three assumptions.

First, valuations are not inflated. The iShares US Medical Devices ETF (IHI) is down 17–20% year to date, trading at a compressed multiple versus its 2021 peak. Public medtech comparables are de-rating, not inflating. As Lisnow puts it: "If rich multiples were the brake, we wouldn't be seeing this."

Second, exits are not weak. Medtech VC exits hit $4.1B in Q1 2026 alone — nearly half of all of 2025 — anchored by EdgeMedical's $2.2B surgical-robotics IPO, according to PitchBook. Strategic acquirers are still paying full price for differentiated assets:

• Boston Scientific / Penumbra: $14.5B
• Danaher / Masimo: $9.9B

"Not a sector investors have given up on," Lisnow writes.

What is actually happening to the capital?

Lisnow's conclusion: "Medtech isn't necessarily being rejected, but instead, being crowded out." AI absorbed 86% of all US VC dollars in H1 2026, according to PitchBook-NVCA Venture Monitor data. With LPs still starved for distributions, 89% of new fund commitments this year went to seasoned, incumbent managers — a tough backdrop for the smaller, specialist funds that anchor early-stage medtech.

Lisnow is living the dynamic firsthand. His own company is raising a pre-seed round, and he reports that the investors still writing early-stage medtech checks are stretched thin, while many specialist funds that once anchored such rounds are not raising new funds of their own. A medtech-focused fund manager at a recent industry conference described a buyer's market for the VCs still active at seed and Series A. In Lisnow's words, the remaining investors are not writing bigger checks because they love the sector more — "they're writing bigger checks because there are fewer of them left standing, and they can afford to be more selective about who they back."

Who is filling the funding gap?

Corporate venture arms have stepped up. Medtronic Ventures, J&J's JJDC and Philips Ventures have all increased their early-stage activity, filling part of the gap left by pulled-back generalist and specialist funds. Lisnow characterizes this as a meaningfully different capital structure than five years ago: less spray-and-pray from generalists, more concentrated conviction from investors — traditional and corporate alike — who understand the regulatory and clinical path a device must walk.

What does this mean for medtech founders?

Lisnow's takeaway for founders: the money got pickier, not gone. "Clinical validation, a clear regulatory pathway, and evidence of real hospital demand aren't optional anymore," he writes. "They're the price of entry to get in front of the smaller pool of investors who are still writing checks."

His framing of the bigger picture: "It's capital discipline colliding with an AI supercycle and an LP liquidity squeeze, while the exit window is quietly reopening underneath the headlines." The open question he leaves for the market is whether Q1's pullback is a temporary AI crowding-out effect or the start of a structural re-rating of the sector — a question that the size of the remaining exit window in 2026 will help answer.